Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Ricard Cervera

Showing results (341-350 of 412) with videos related to

Pageof 42
Sort By:
Arthritis and Rheumatism|December 14, 2004
Early response to immunosuppressive therapy predicts good renal outcome in lupus nephritis: lessons from long-term followup of patients in the Euro-Lupus Nephritis TrialFrédéric A Houssiau, Carlos Vasconcelos, David D'Cruz, et al.
The Journal of Rheumatology|December 17, 2018
Use of Consensus Methodology to Determine Candidate Items for Systemic Lupus Erythematosus Classification CriteriaSindhu R Johnson, Dinesh Khanna, David Daikh, et al.
Laboratory Investigation; a Journal of Technical Methods and Pathology|April 12, 2023
Associations Among Antiphospholipid Antibody Types, Isotypes, and Titers: An AntiPhospholipid Syndrome Alliance for Clinical Trials and InternatiOnal Networking (APS ACTION) StudyElena Gkrouzman, Rohan Willis, Danieli Andrade, et al.
Arthritis and Rheumatism|September 5, 2002
Immunosuppressive therapy in lupus nephritis: the Euro-Lupus Nephritis Trial, a randomized trial of low-dose versus high-dose intravenous cyclophosphamideFrédéric A Houssiau, Carlos Vasconcelos, David D'Cruz, et al.
Lupus Science & Medicine|October 7, 2025
Prediction model for renal outcomes in Latin American Mestizo patients with pure proliferative lupus nephritisArturo Villalobos Navarro, Marc Xipell, Estefanía Garduño Hernández, et al.
Frontiers in Immunology|November 3, 2025
A proteomic map of thromboinflammatory signatures in antiphospholipid syndrome: results from antiphospholipid syndrome alliance for clinical trials and international networking (APS ACTION) registryAlexander Pine, Ayesha Butt, Laura Andreoli, et al.
Frontiers in Immunology|June 11, 2026
Correction: Anti-β2GPI IgG display a broad reactivity against different β2GPI domains beyond domain 1: results from the APS ACTION and multi-center Italian cohortsClaudia Grossi, Caterina Bodio, Suresh Kumar, et al.
Journal of Autoimmunity|April 10, 2009
Prevalence of hepatitis C serum antibody in autoimmune diseasesNancy Agmon-Levin, Maya Ram, Ori Barzilai, et al.
Bone Marrow Transplantation|August 19, 2025
Autologous haematopoietic stem cell transplantation for rheumatic diseases: best practice recommendations from the EBMT Practice Harmonization and Guidelines CommitteeTobias Alexander, Elisa Roldan, Nicoletta Del Papa, et al.
Frontiers in Immunology|May 18, 2026
Anti-β2GPI IgG display a broad reactivity against different β2GPI domains beyond domain 1: results from the APS ACTION and multi-center Italian cohortsClaudia Grossi, Caterina Bodio, Suresh Kumar, et al.
Pageof 42

Showing results (341-350 of 412) with videos related to

Sort By:
Pageof 42
Arthritis and Rheumatism|December 14, 2004
Early response to immunosuppressive therapy predicts good renal outcome in lupus nephritis: lessons from long-term followup of patients in the Euro-Lupus Nephritis TrialFrédéric A Houssiau, Carlos Vasconcelos, David D'Cruz, et al.
The Journal of Rheumatology|December 17, 2018
Use of Consensus Methodology to Determine Candidate Items for Systemic Lupus Erythematosus Classification CriteriaSindhu R Johnson, Dinesh Khanna, David Daikh, et al.
Laboratory Investigation; a Journal of Technical Methods and Pathology|April 12, 2023
Associations Among Antiphospholipid Antibody Types, Isotypes, and Titers: An AntiPhospholipid Syndrome Alliance for Clinical Trials and InternatiOnal Networking (APS ACTION) StudyElena Gkrouzman, Rohan Willis, Danieli Andrade, et al.
Arthritis and Rheumatism|September 5, 2002
Immunosuppressive therapy in lupus nephritis: the Euro-Lupus Nephritis Trial, a randomized trial of low-dose versus high-dose intravenous cyclophosphamideFrédéric A Houssiau, Carlos Vasconcelos, David D'Cruz, et al.
Lupus Science & Medicine|October 7, 2025
Prediction model for renal outcomes in Latin American Mestizo patients with pure proliferative lupus nephritisArturo Villalobos Navarro, Marc Xipell, Estefanía Garduño Hernández, et al.
Frontiers in Immunology|November 3, 2025
A proteomic map of thromboinflammatory signatures in antiphospholipid syndrome: results from antiphospholipid syndrome alliance for clinical trials and international networking (APS ACTION) registryAlexander Pine, Ayesha Butt, Laura Andreoli, et al.
Frontiers in Immunology|June 11, 2026
Correction: Anti-β2GPI IgG display a broad reactivity against different β2GPI domains beyond domain 1: results from the APS ACTION and multi-center Italian cohortsClaudia Grossi, Caterina Bodio, Suresh Kumar, et al.
Journal of Autoimmunity|April 10, 2009
Prevalence of hepatitis C serum antibody in autoimmune diseasesNancy Agmon-Levin, Maya Ram, Ori Barzilai, et al.
Bone Marrow Transplantation|August 19, 2025
Autologous haematopoietic stem cell transplantation for rheumatic diseases: best practice recommendations from the EBMT Practice Harmonization and Guidelines CommitteeTobias Alexander, Elisa Roldan, Nicoletta Del Papa, et al.
Frontiers in Immunology|May 18, 2026
Anti-β2GPI IgG display a broad reactivity against different β2GPI domains beyond domain 1: results from the APS ACTION and multi-center Italian cohortsClaudia Grossi, Caterina Bodio, Suresh Kumar, et al.
Pageof 42